Genotyping analysis and 18FDG uptake in breast cancer patients: A preliminary research

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Bravatà, Valentina ^a   Stefano, Alessandro ^a   Cammarata, Francesco P ^a   Minafra, Luigi ^a   Russo, Giorgio ^a   Nicolosi, Stefania ^a   Pulizzi, Sabina ^b   Gelfi, Cecilia ^a,c   Gilardi, Maria C ^a,d,e   Messa, Cristina ^a,e,f  

^a IBFM CNR LATO   (Italy)

^b Fondazione Istituto San Raffaele G Giglio   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f SAN GERARDO HOSPITAL   (Italy)

Author keywords

Breast cancer; PET CT; Single nucleotide polymorphisms; SUVmax; SUVpvc

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER PATIENT; CAPILLARY ELECTROPHORESIS; CLINICAL ARTICLE; CLINICAL RESEARCH; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DNA SEQUENCE; DRUG UPTAKE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST TUMOR; COMPUTER ASSISTED TOMOGRAPHY; GENETICS; METABOLISM; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; GENOTYPE; HUMANS; MULTIMODAL IMAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84876811654     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-23     Document Type: Article

References (47)

1. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. Kamangar F, Dores GM, Anderson WF, J Clin Oncol 2006 24 2137 2150 10.1200/JCO.2005.05.2308 16682732 (Pubitemid 46655601)
2. Expression profiling technology: its contribution to our understanding of breast cancer. Rakha EA, El-Sayed ME, Reis-Filho JS, Ellis IO, Histopathology 2008 52 67 81 18171418 (Pubitemid 350265184)
3. "Omics" of HER2 Positive Breast Cancer. Bravatà V, Cammarata FP, Forte GI, Minafra L, OMICS 2013 17 119 129 10.1089/omi.2012.0099 23421906
4. Unmasking epithelial-mesenchymal transition in a breast cancer primary culture: a study report. Minafra L, Norata R, Bravatà V, Viola M, Lupo C, Gelfi C, Messa C, BMC Res Notes 2012 5 343 10.1186/1756-0500-5-343 22759679
5. Imaging and 'omic' methods for the molecular diagnosis of cancer. Bohndiek SE, Brindle KM, Expert Rev Mol Diagn 2010 10 417 434 10.1586/erm.10.20 20465497
6. PET-CT in radiation oncology: the impact on diagnosis, treatment planning, and assessment of treatment response. Heron DE, Andrade RS, Beriwal S, Smith RP, Am J Clin Oncol 2008 31 352 362 10.1097/COC.0b013e318162f150 18845994
7. Putative molecular signatures for the imaging of prostate cancer. Yang SY, Adelstein J, Kassis AI, Expert Rev Mol Diagn 2010 10 65 74 10.1586/erm.09.73 20014923
8. A multistage genome-wide association study in breast cancer identifi es two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, Hankinson SE, Hutchinson A, Wang Z, Yu K, Chatterjee N, Garcia-Closas M, Gonzalez-Bosquet J, Prokunina-Olsson L, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Diver R, Prentice R, Jackson R, Kooperberg C, Chlebowski R, Lissowska J, Nat Genet 2009 41 579 584 10.1038/ng.353 19330030
9. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover RN, Thomas G, Chanock SJ, Nat Genet 2007 39 870 874 10.1038/ng2075 17529973 (Pubitemid 47014500)
10. Breast cancer single-nucleotide polymorphisms: statistical significance and clinical utility. Offit K, J Natl Cancer Inst 2009 101 973 975 10.1093/jnci/djp184 19567420
11. Common genetic variation and human traits. Goldstein DB, N Engl J Med 2009 360 1696 1698 10.1056/NEJMp0806284 19369660
12. Genomic profiles for disease risk: predictive or premature? Offit K, JAMA 2008 299 1353 1355 10.1001/jama.299.11.1353 18349097 (Pubitemid 351439082)
13. The 936C > T polymorphism of the gene for vascular endothelial growth factor is associated with 18F-fluorodeoxyglucose uptake. Wolf G, Aigner RM, Schaffler G, Langsenlehner U, Renner W, Samonigg H, Yazdani-Biuki B, Krippl P, Breast Cancer Res Treat 2004 88 205 208 10.1007/s10549-004-0724-2 15609122 (Pubitemid 40137298)
14. The XbaI G > T polymorphism of the glucose transporter 1 gene modulates 18F-FDG uptake and tumor aggressiveness in breast cancer. Grabellus F, Sheu SY, Bachmann HS, Lehmann N, Otterbach F, Heusner TA, Antoch G, Bockisch A, Kimmig R, Schmid KW, Stahl AR, J Nucl Med 2010 51 1191 1197 10.2967/jnumed.110.075721 20679470
15. The association of 18F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. SLC2A1 polymorphisms and FDG-PET in NSCLC patients. Kim SJ, Hwang SH, Kim IJ, Lee MK, Lee CH, Lee SY, Lee EY, J Exp Clin Cancer Res 2010 12 29 69
16. Single nucleotide polymorphisms in the peroxisome proliferator-activated receptor delta gene are associated with skeletal muscle glucose uptake. Vänttinen M, Nuutila P, Kuulasmaa T, Pihlajamäki J, Hällsten K, Virtanen KA, Lautamäki R, Peltoniemi P, Takala T, Viljanen AP, Knuuti J, Laakso M, Diabetes 2005 54 3587 3591 10.2337/diabetes.54.12.3587 16306381 (Pubitemid 43334355)
17. Association of the VEGF 936C > T polymorphism with FDG uptake, clinical, histopathological, and metabolic response in patients with adenocarcinomas of the esophagogastric junction. Lorenzen S, Panzram B, Keller G, Lordick F, Herrmann K, Becker K, Langer R, Schwaiger M, Siewert JR, Ott K, Mol Imaging Biol 2011 13 178 186 10.1007/s11307-010-0330-0 20449668
18. The serotonin transporter genotype is associated with intermediate brain phenotypes that depend on the context of eliciting stressor. Kalin NH, Shelton SE, Fox AS, Rogers J, Oakes TR, Davidson RJ, Mol Psychiatry 2008 13 1021 1027 10.1038/mp.2008.37 18414408
19. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. Macheda ML, Rogers S, Best JD, J Cell Physiol 2005 202 654 662 10.1002/jcp.20166 15389572 (Pubitemid 40175840)
20. Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL, J Nucl Med 1996 37 1042 1047 8683298 (Pubitemid 126447147)
21. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Grabellus F, Nagarajah J, Bockisch A, Schmid KW, Sheu SY, Clin Nucl Med 2012 37 121 127 10.1097/RLU.0b013e3182393599 22228332
22. 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II. Hamada K, Tomita Y, Qiu Y, Zhang B, Ueda T, Myoui A, Higuchi I, Yoshikawa H, Aozasa K, Hatazawa J, Ann Nucl Med 2008 22 699 705 10.1007/s12149-008-0173-9 18982473
23. 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. Westerterp M, Sloof GW, Hoekstra OS, Ten Kate FJ, Meijer GA, Reitsma JB, Boellaard R, Van Lanschot JJ, Molthoff CF, J Cancer Res Clin Oncol 2008 134 227 236 17653575 (Pubitemid 350234068)
24. Polymorphisms of the glucose transporter (GLUT1) gene are associated with diabetic nephropathy. Hodgkinson AD, Millward BA, Demaine AG, Kidney Int 2001 59 985 989 10.1046/j.1523-1755.2001.059003985.x 11231353 (Pubitemid 32206861)
25. Glucose transporter polymorphisms are associated with clear-cell renal carcinoma. Page T, Hodgkinson AD, Ollerenshaw M, Hammonds JC, Demaine AG, Cancer Genet Cytogenet 2005 163 151 155 10.1016/j.cancergencyto.2005.07.004 16337858 (Pubitemid 41760412)
26. Analysis of a promoter polymorphism of the GLUT1 gene in patients with hepatocellular carcinoma. Amann T, Kirovski G, Bosserhoff AK, Hellerbrand C, Mol Membr Biol 2011 28 182 186 10.3109/09687688.2011.554447 21332301
27. HIF-1 and tumor progression: pathophysiology and therapeutics. Semenza GL, Trends Mol Med 2002 8 62 S67 10.1016/S1471-4914(02)02317-1 11927290 (Pubitemid 34297081)
28. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Semenza GL, Curr Opin Genet Dev 1998 8 588 594 10.1016/S0959-437X(98)80016-6 9794818 (Pubitemid 28477364)
29. The expression and distribution of the hypoxia-inducible factors HIF1-alpha and HIF2-alpha in normal human tissues, cancers, and tumorassociated macrophages. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL, Am J Pathol 2000 57 411 421 (Pubitemid 30626905)
30. Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Fu XS, Choi E, Bubley GJ, Balk SP, Prostate 2005 63 215 221 10.1002/pros.20190 15538748 (Pubitemid 40571055)
31. C2028T polymorphism in exon 12 and dinucleotide repeat polymorphism in intron 13 of the HIF1-alpha gene define HIF1-alpha protein expression in non-small cell lung cancer. Koukourakis MI, Papazoglou D, Giatromanolaki A, Panagopoulos I, Maltezos E, Harris AL, Gatter KC, Sivridis E, Lung Cancer 2006 53 257 262 10.1016/j.lungcan.2006.05.025 16837101 (Pubitemid 44209281)
32. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Covello KL, Kehler J, Yu H, Gordan JD, Arsham AM, Hu CJ, Labosky PA, Simon MC, Keith B, Genes Dev 2006 20 557 570 10.1101/gad.1399906 16510872 (Pubitemid 43345322)
33. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Scortegagna M, Ding K, Oktay Y, Gaur A, Thurmond F, Yan LJ, Marck BT, Matsumoto AM, Shelton JM, Richardson JA, Bennett MJ, Garcia JA, Nat Genet 2003 35 331 340 10.1038/ng1266 14608355 (Pubitemid 37486916)
34. Hypoxia-inducible factor-2alpha transactivates Abcg2 and promotes cytoprotection in cardiac side population cells. Martin CM, Ferdous A, Gallardo T, Humphries C, Sadek H, Caprioli A, Garcia JA, Szweda LI, Garry MG, Garry DJ, Circ Res 2008 102 1075 1081 10.1161/CIRCRESAHA.107.161729 18356544 (Pubitemid 351667861)
35. Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Chang-Claude J, Ambrosone CB, Lilla C, Kropp S, Helmbold I, Von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Popanda O, Br J Cancer 2009 100 1680 1686 10.1038/sj.bjc.6605036 19367277
36. Partial volume correction strategies for quantitative FDG PET in oncology. Hoetjes NJ, Van Velden FH, Hoekstra OS, Hoekstra CJ, Krak NC, Lammertsma AA, Boellaard R, Eur J Nucl Med Mol Imaging 2010 37 1679 1687 10.1007/s00259-010-1472-7 20422184
37. Partial-volume effect in PET tumor imaging. Soret M, Bacharach SL, Buvat I, J Nucl Med 2007 48 932 945 10.2967/jnumed.106.035774 17504879 (Pubitemid 46909922)
38. PVE correction in PET-CT whole-body oncological studies from PVE-affected images. Gallivanone F, Stefano A, Canevari C, Gianolli L, Messa C, Gilardi MC, Castiglioni I, IEEE Trans Nucl Sci 2011 58 736 747
39. The Human Gene Mutation Database http://www.hgmd.cf.ac.uk
40. The dbSNP Short Genetic Variations database http://www.ncbi.nlm.nih.gov
41. Primer3 on the WWW for general users and for biologist programmers. Rozen S, Skaletsky HJ, Bioinformatics Methods and Protocols: Methods in Molecular Biology Totowa, NJ: Humana Press, Krawetz S, Misener S, 2000 365 386 http://fokker.wi.mit.edu/primer3
42. Breast cancer as an acquired thrombophilic state. Kyriazi V, J Breast Cancer. 2012 15 148 156 10.4048/jbc.2012.15.2.148 22807931
43. MTHFR polymorphisms and breast cancer risk. Hosseini M, Houshmand M, Ebrahimi A, Arch Med Sci. 2011 7 134 137 22291746
44. Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. Jakubowska A, Gronwald J, Menkiszak J, Górski B, Huzarski T, Byrski T, Edler L, Lubiński J, Scott RJ, Hamann U, Breast Cancer Res Treat 2007 104 299 308 10.1007/s10549-006-9417-3 17063264 (Pubitemid 47231276)
45. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Matakidou A, El Galta R, Webb EL, Rudd MF, Bridle H, GELCAPS Consortium, Eisen T, Houlston RS, Hum Mol Genet 2007 16 2333 2340 10.1093/hmg/ddm190 17855454 (Pubitemid 47423899)
46. A tutorial on statistical methods for population association studies. Balding DJ, Nat Rev Genet 2006 7 10 781 791 10.1038/nrg1916 16983374 (Pubitemid 44413222)
47. Geographical and ethnic variation of the 677C > T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. Wilcken B, Bamforth F, Li Z, Zhu H, Ritvanen A, Renlund M, Stoll C, Alembik Y, Dott B, Czeizel AE, Gelman-Kohan Z, Scarano G, Bianca S, Ettore G, Tenconi R, Bellato S, Scala I, Mutchinick OM, López MA, De Walle H, Hofstra R, Joutchenko L, Kavteladze L, Bermejo E, Martínez-Frías ML, Gallagher M, Erickson JD, Vollset SE, Mastroiacovo P, Andria G, J Med Genet 2003 40 619 625 10.1136/jmg.40.8.619 12920077 (Pubitemid 37046918)